This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processes behind diversification, including how companies identify emerging opportunities, leverage external innovation, allocate resources across modalities and disease areas, and adapt to evolving market and scientific landscapes. Panelists will discuss the tools and decision-making frameworks used to support sustainable innovation, balancing risk and reward for long-term impact. The session will also examine how collaboration accelerates diversification and influences investment decisions. Attendees will gain insight into how various organizational structures and partnering approaches shape pipeline development for resilience and relevance in the current healthcare environment.